An Open-Label, Phase Ib Study to Assess the Long Term Safety Profile of Pazopanib in Cancer Patients.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 23 May 2017
At a glance
- Drugs Pazopanib (Primary) ; Antineoplastics; Lapatinib
- Indications Glioblastoma; Solid tumours
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; Novartis
- 16 May 2017 Planned primary completion date changed from 1 Feb 2013 to 31 Dec 2017.
- 11 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 12 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016, as reported by ClinicalTrials.gov.